Eric Lefebvre
Chief Tech/Sci/R&D Officer bij PLIANT THERAPEUTICS, INC.
Vermogen: 3 M $ op 31-03-2024
Profiel
Eric Lefebvre is currently serving as a Board of Director at Fonds D Investissement De La Culture Et Des Communications, LP.
He is also the Chief Medical Officer at Pliant Therapeutics, Inc. since 2018.
Additionally, he is a Member of The CIHR Canadian HIV Trials Network and the Canadian Association For HIV Research.
In his former positions, Dr. Lefebvre worked as the Director-Medical Affairs at GlaxoSmithKline, Inc. from 2001 to 2003.
He also served as an Independent Director at CymaBay Therapeutics, Inc. from 2022 to 2024.
Furthermore, he held the position of Head-Global Medical Affairs at Janssen Pharmaceuticals, Inc. from 2003 to 2007.
Dr. Lefebvre was the Chief Medical Officer at Tobira Therapeutics, Inc. and Vice President-Research & Development at Allergan Ltd.
(Ireland) from 2016 to 2018.
He also worked as a Principal at GlaxoSmithKline Pharmaceuticals SA (Belgium).
From 2012 to 2016, he served as the Chief Medical Officer at Tobira Therapeutics, Inc.Dr. Lefebvre obtained a doctorate degree from the University of Montréal and an undergraduate degree from College d'Enseignement General et Prof.
Edouard-Montpetit.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
23-01-2024 | 199 820 ( 0.33% ) | 3 M $ | 31-03-2024 |
Actieve functies van Eric Lefebvre
Bedrijven | Functie | Begin |
---|---|---|
PLIANT THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01-05-2018 |
The CIHR Canadian HIV Trials Network
The CIHR Canadian HIV Trials Network Miscellaneous Commercial ServicesCommercial Services CIHR Canadian HIV Trials Network develops treatments, preventions, and a cure for HIV and related health conditions. The company was founded by Martin Schechter, John Ruedy and Julio Montaner in 1990 and is headquartered in Vancouver, Canada. | Corporate Officer/Principal | - |
Canadian Association For HIV Research | Corporate Officer/Principal | - |
Fonds D Investissement De La Culture Et Des Communications, LP
Fonds D Investissement De La Culture Et Des Communications, LP Investment ManagersFinance Fonds D Investissement De La Culture Et Des Communications is an Independent Venture Capital firm founded in 1997.The firm is headquartered in Montréal. | Director/Board Member | - |
Eerdere bekende functies van Eric Lefebvre
Bedrijven | Functie | Einde |
---|---|---|
CYMABAY THERAPEUTICS, INC. | Director/Board Member | 22-03-2024 |
ALLERGAN PLC | Chief Tech/Sci/R&D Officer | 01-04-2018 |
TOBIRA THERAPEUTICS INC | Chief Tech/Sci/R&D Officer | 01-11-2016 |
Janssen Pharmaceuticals, Inc.
Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ. | Chief Tech/Sci/R&D Officer | 01-01-2007 |
GlaxoSmithKline, Inc.
GlaxoSmithKline, Inc. Pharmaceuticals: MajorHealth Technology GlaxoSmithKline, Inc. manufactures and markets pharmaceutical products. The company develops medicines to prevent infections that cause serious medical problems such as respiratory illnesses, diabetes, viral control, infections, and central nervous system disorders. The company is headquartered in Mississauga, Canada. | Corporate Officer/Principal | 01-01-2003 |
Opleiding van Eric Lefebvre
University of Montréal | Doctorate Degree |
College d'Enseignement General et Prof. Edouard-Montpetit | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
PLIANT THERAPEUTICS, INC. | Health Technology |
Bedrijven in privébezit | 10 |
---|---|
CymaBay Therapeutics, Inc.
CymaBay Therapeutics, Inc. BiotechnologyHealth Technology CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline includes Seladelpar, MBX-2982, CB-0406, and CB-001. The company was founded on October 5, 1988 and is headquartered in Newark, CA. | Health Technology |
Janssen Pharmaceuticals, Inc.
Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ. | Health Technology |
GlaxoSmithKline, Inc.
GlaxoSmithKline, Inc. Pharmaceuticals: MajorHealth Technology GlaxoSmithKline, Inc. manufactures and markets pharmaceutical products. The company develops medicines to prevent infections that cause serious medical problems such as respiratory illnesses, diabetes, viral control, infections, and central nervous system disorders. The company is headquartered in Mississauga, Canada. | Health Technology |
Tobira Therapeutics, Inc. /Old/
Tobira Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which focuses on developing and commercializing of therapies to treat liver disease, HIV, fibrosis and inflammation. Its lead product candidate, cenicriviroc or CVC, is a proprietary immunomodulator that may be used to treat a number of diseases, including NASH, kidney fibrosis, HIV-1 and others. The company was founded by Eckard Weber in September 2006 and is headquartered in South San Francisco, CA. | Health Technology |
Allergan Ltd. (Ireland)
Allergan Ltd. (Ireland) Pharmaceuticals: MajorHealth Technology Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded in 1982 and is headquartered in Dublin, Ireland. | Health Technology |
GlaxoSmithKline Pharmaceuticals SA (Belgium)
GlaxoSmithKline Pharmaceuticals SA (Belgium) Pharmaceuticals: MajorHealth Technology GlaxoSmithKline Pharmaceuticals SA develops and manufactures pharmaceuticals and vaccines. The company is headquartered in Wavre, Belgium. | Health Technology |
Tobira Therapeutics, Inc.
Tobira Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company was founded on October 6, 2006 and is headquartered in Madison, NJ. | Health Technology |
The CIHR Canadian HIV Trials Network
The CIHR Canadian HIV Trials Network Miscellaneous Commercial ServicesCommercial Services CIHR Canadian HIV Trials Network develops treatments, preventions, and a cure for HIV and related health conditions. The company was founded by Martin Schechter, John Ruedy and Julio Montaner in 1990 and is headquartered in Vancouver, Canada. | Commercial Services |
Canadian Association For HIV Research | |
Fonds D Investissement De La Culture Et Des Communications, LP
Fonds D Investissement De La Culture Et Des Communications, LP Investment ManagersFinance Fonds D Investissement De La Culture Et Des Communications is an Independent Venture Capital firm founded in 1997.The firm is headquartered in Montréal. | Finance |